## Abstract ## BACKGROUND. Hypothyroidism is a potential complication after radiation therapy (RT) when treatment fields include the thyroid. The authors assessed risk of hypothyroidism in breast cancer patients who were receiving RT to a supraclavicular field, which typically includes a portion o
Radiation dose and breast cancer risk in patients treated for cancer of the cervix
✍ Scribed by John D. Boice Jr.; Maria Blettner; Ruth A. Kleinerman; Göran Engholm; Marilyn Stovall; Hermann Lisco; Donald F. Austin; Antonio Bosch; Linda Harlan; Edward T. Krementz; Howard B. Latourette; James A. Merrill; Lester J. Peters; Milford D. Schulz; Jean Wactawski; Hans H. Storm; Elisabet Björkholm; Folke Pettersson; Cm. Janine Bell; Michel P. Coleman; Patricia Fraser; Frank E. Neal; Patricia Prior; N. Won Choi; T. Gregory Hislop; Maria Koch; Nancy Kreiger; Dorothy Robb; Diane Robson; D. H. Thomson; H. Lochmüller; Dietrich Von Fournier; Rolf Frischkorn; Kjell E. Kjørstad; Arja Rimpelä; Marie-Héléne Pejovic; Vera Pompe Kirn; Hanna Stankusova; Paola Pisani; Kristjan Sigurdsson; George B. Hutchison; Brian Macmahon
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- French
- Weight
- 990 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abbreviations: CI, confidence interval(s); df, degrees of freedom; Gy, gray = 100 rad; kVp, kilovolts peak; ML, maximum likelihood; PY-Gy, person-years of observation multiplied by the average dose in gray; RR, relative risk.
📜 SIMILAR VOLUMES
W e read the interesting article by Jagsi et al on the increased rates of coronary artery disease in patients treated with radiation therapy for early-stage breast cancer. 1 In their study, those authors concluded that the findings support further assessment of clinical outcomes when newer technique
## Abstract The present study aimed to investigate the clinical relevance of disseminated tumor cells (DTC) in breast cancer patients before and after high‐dose adjuvant chemotherapy with or without progenitor stem‐cell support. One hundred and eighteen high‐risk stage II breast cancer patients ent